If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


 
ARCH Venture Fund X, L.P.
 
Signature:ARCH Venture Partners X, L.P.
Name/Title:its General Partner
Date:08/11/2025
 
Signature:ARCH Venture Partners X, LLC
Name/Title:its General Partner
Date:08/11/2025
 
Signature:/s/ Mark McDonnell
Name/Title:Mark McDonnell, as Attorney-in-Fact for Robert Nelsen, Managing Director
Date:08/11/2025
 
ARCH Venture Fund X Overage, L.P.
 
Signature:ARCH Venture Partners X Overage, L.P.
Name/Title:its General Partner
Date:08/11/2025
 
Signature:ARCH Venture Partners X, LLC
Name/Title:its General Partner
Date:08/11/2025
 
Signature:/s/ Mark McDonnell
Name/Title:Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:08/11/2025
 
ARCH Venture Fund XII, L.P.
 
Signature:ARCH Venture Partners XII, L.P.
Name/Title:its General Partner
Date:08/11/2025
 
Signature:ARCH Venture Partners XII, LLC
Name/Title:its General Partner
Date:08/11/2025
 
Signature:/s/ Mark McDonnell
Name/Title:Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:08/11/2025
 
ARCH Venture Partners X, L.P.
 
Signature:ARCH Venture Partners X, LLC
Name/Title:its General Partner
Date:08/11/2025
 
Signature:/s/ Mark McDonnell
Name/Title:Mark McDonnell, as Attorney-in-Fact for Robert Nelsen, Managing Director
Date:08/11/2025
 
ARCH Venture Partners X Overage, L.P.
 
Signature:ARCH Venture Partners X, LLC
Name/Title:its General Partner
Date:08/11/2025
 
Signature:/s/ Mark McDonnell
Name/Title:Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:08/11/2025
 
ARCH Venture Partners XII, L.P.
 
Signature:ARCH Venture Partners XII, LLC
Name/Title:its General Partner
Date:08/11/2025
 
Signature:/s/ Mark McDonnell
Name/Title:Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:08/11/2025
 
ARCH Venture Partners X, LLC
 
Signature:/s/ Mark McDonnell
Name/Title:Mark McDonnell, as Attorney-in-Fact for Robert Nelsen, Managing Director
Date:08/11/2025
 
ARCH Venture Partners XII, LLC
 
Signature:/s/ Mark McDonnell
Name/Title:Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Date:08/11/2025
 
Robert Nelsen
 
Signature:/s/ Mark McDonnell
Name/Title:Mark McDonnell, as Attorney-in-Fact for Robert Nelsen
Date:08/11/2025
 
Keith Crandell
 
Signature:/s/ Mark McDonnell
Name/Title:Mark McDonnell, as Attorney-in-Fact for Keith Crandell
Date:08/11/2025
 
Kristina Burow
 
Signature:/s/ Mark McDonnell
Name/Title:Mark McDonnell, as Attorney-in-Fact for Kristina Burow
Date:08/11/2025
 
Steven Gillis
 
Signature:/s/ Mark McDonnell
Name/Title:Mark McDonnell, as Attorney-in-Fact for Steven Gillis
Date:08/11/2025
Comments accompanying signature:
*This Schedule 13D was executed by Mark McDonnell pursuant to Powers of Attorney filed as Exhibit 24 and 24.1 to the Form 3 relating to the beneficial ownership of shares of Prime Medicine, Inc. by the Reporting Persons filed with the Securities Exchange Commission on October 19, 2022 and pursuant to a Power of Attorney filed as Exhibit 24.4 to the Form 3 relating to the beneficial ownership of shares by the Reporting Persons of Neumora Therapeutics, Inc. filed with the Securities Exchange Commission on September 14, 2023 and incorporated herein in its entirety by reference.